Huai-Cheng Lee

Title: Innovations of Huai-Cheng Lee in Neurodegenerative Disorder Treatments

Introduction

Huai-Cheng Lee is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of neurodegenerative disorders. His innovative approach combines both immediate-release and sustained-release drug formulations, showcasing his commitment to advancing medical science.

Latest Patents

Huai-Cheng Lee holds a patent for an oral dosage formulation that contains both immediate-release and sustained-release drugs for treating neurodegenerative disorders. This formulation includes an acetylcholinesterase inhibitor (AChEI) that releases more than 80% of the drug within 60 minutes, alongside memantine, which has a dissolution rate of over 80% within 12 hours. This dual-action approach aims to enhance the efficacy of treatment for patients suffering from these debilitating conditions.

Career Highlights

Lee is associated with Center Laboratories, Inc., where he continues to innovate and develop new pharmaceutical solutions. His work is characterized by a strong focus on improving patient outcomes through advanced drug delivery systems. His dedication to research and development has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Some of Huai-Cheng Lee's coworkers include Chien-Fen Chen and Chuen-Lin Din. Their collaborative efforts contribute to the ongoing research and development initiatives at Center Laboratories, Inc., fostering an environment of innovation and teamwork.

Conclusion

Huai-Cheng Lee's contributions to the field of neurodegenerative disorder treatments exemplify the impact of innovative thinking in pharmaceuticals. His patent for a unique oral dosage formulation highlights the potential for improved patient care through advanced drug delivery methods.